use disorders from 61.4% to 42.6%, for an average annual percentage change of −2.6 (95% CI, −3.1 to −2.0) and among those without drug use disorders from 26.0% to 17.7%, for an average annual percentage change of −3.0 (95% CI, −3.2 to −2.7), as shown in eTable 1.1 Notably, the difference in past-month prevalence of cigarette smoking between individuals with and without drug use disorders declined in the US from 35.5% in 2006 to 25.0% in 2019.1 Moreover, our study1 found that in the US from 2006 to 2019, past-month prevalence of cigarette smoking significantly declined among those with past-year MDE from 37.3% to 24.2%, among those with past-year SUD from 46.5% to 35.8%, and among those with past-year MDE and SUD from 50.7% to 37.0%. From 2006 to 2019, the difference in past-month prevalence of cigarette smoking between individuals with and without MDE declined significantly from 11.5% to 6.6%.1

Prior studies2-4 have not demonstrated declines in past-month prevalence of cigarette smoking in individuals with SUD and other mental illnesses, highlighting the novelty of our findings.1 Furthermore, among adults with MDE and/or SUD, our results showed that the lifetime prevalence of cigarette smoking did not decline as much as past-month prevalence, indicating that the reductions in past-month smoking were due to quitting at some time after onset of smoking. Thus, tobacco cessation explains the relative improvements in past-month prevalence of cigarette smoking.1

Our study1 demonstrates that progress has been made by public health tobacco control measures and prevention intervention efforts for adults in the US, including those with MDE or SUD. However, higher past-month prevalence of smoking persists among adults with MDE or SUD, highlighting the ongoing need for smoking cessation efforts that target these individuals. We hope that our study will stimulate future work to better address cigarette smoking among people with SUD and other mental illnesses.

Beth Han, MD, PhD, MPH
Douglas Tipperman, MSW
Wilson M. Compton, MD, MPE

Author Affiliations: National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland (Han, Compton); Substance Abuse and Mental Health Services Administration, Rockville, Maryland (Tipperman).

Corresponding Author: Wilson M. Compton, MD, MPE, National Institute on Drug Abuse, National Institutes of Health, 3WFN Room 09D18, MSC 6025, 301 N Stonestreet Ave, Bethesda, MD 20892 (wcompton@nida.nih.gov).

Conflict of Interest Disclosures: Dr Compton reported owning stock in General Electric, 3M Co, and Pfizer Inc. No other disclosures were reported.

Disclaimer: The findings and conclusions of this study are those of the authors and do not necessarily reflect the views of the National Institute on Drug Abuse of the National Institutes of Health, the Substance Abuse and Mental Health Services Administration, and the US Department of Health and Human Services.


Correction
Incorrect Reference: In the US Preventive Services Task Force review titled “Screening for Impaired Visual Acuity in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force,”1 published in the June 7, 2022, issue of JAMA, a reference was incorrect. Reference 10 should have appeared as “Evans JR, Lawrenceon JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2017;7(7):CD000254. doi:10.1002/14651858.CD000254.pub4.” This article was corrected online.


Guidelines for Letters

Letters discussing a recent JAMA article should be submitted within 4 weeks of the article’s publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at https://jamanetwork.com/journals/jama/pages/instructions-for-authors. A signed statement for authors’ responsibility, financial disclosure, copyright transfer, and acknowledgment are required before publication. Letters should be submitted via the JAMA online submission and review system at https://manuscripts.jama.com. For technical assistance, please contact jama-letters@jamanetwork.org.

Section Editors: Jody W. Zyke, MD, Deputy Editor; Kristin Walter, MD, Senior Editor.